The drug inhibits progression of epidermolysis bullosa in skin. (IMAGE)

Tampere University

The drug inhibits progression of epidermolysis bullosa in skin.

Caption

The drug inhibits progression of epidermolysis bullosa in skin. Recessive dystrophic pidermolysis bullosa (RDEB) leads to excessive deposition of fibrosis (COL I) in the skin in response to skin fragility. Fibrosis is produced by cells called myofibroblasts (α-SMA), which arise from normal fibroblasts. Both myofibroblasts (α-SMA) and fibrosis (COL I) formation can be inhibited by the drug (DCN-tCRK) developed by Tampere University Research team.

Credit

The original image published in Pemmari et al. Mol Ther 2020

Usage Restrictions

The image may only be used when reporting on this topic.

License

Original content

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.